HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Examining the neuroprotective effects of protocatechuic acid and chrysin on in vitro and in vivo models of Parkinson disease.

Abstract
Polypharmacology-based strategies using drug combinations with different mechanisms of action are gaining increasing attention as a novel methodology to discover potentially innovative medicines for neurodegenerative disorders. We used this approach to examine the combined neuroprotective effects of two polyphenols, protocatechuic acid (PCA) and chrysin, identified from the fruits of Alpinia oxyphylla. Our results demonstrated synergistic neuroprotective effects, with chrysin enhancing the protective effects of PCA, resulting in greater cell viability and decreased lactate dehydrogenase release from 6-hydroxydopamine-treated PC12 cells. Their combination also significantly attenuated chemically induced dopaminergic neuron loss in both zebrafish and mice. We examined the molecular mechanisms underlying these collective cytoprotective effects through proteomic analysis of treated PC12 cells, resulting in the identification of 12 regulated proteins. Two were further characterized, leading to the determination that pretreatment with PCA and chrysin resulted in (i) increased nuclear factor-erythroid 2-related factor 2 protein expression and transcriptional activity; (ii) modulation of cellular redox status with the upregulated expression of hallmark antioxidant enzymes, including heme oxygenase-1, superoxide dismutase, and catalase; and (iii) decreased levels of malondialdehyde, a known lipid peroxidation product. Treatment with PCA and chrysin also inhibited activation of nuclear factor-κB and expression of inducible nitric oxide synthase. Our findings suggest that natural products, when used in combination, can be effective potential therapeutic agents for treating diseases such as Parkinson disease. A therapy involving both PCA and chrysin exhibits its enhanced neuroprotective effects through a combination of cellular mechanisms: antioxidant cytoprotection and anti-inflammation.
AuthorsZaijun Zhang, Guohui Li, Samuel S W Szeto, Cheong Meng Chong, Quan Quan, Chen Huang, Wei Cui, Baojian Guo, Yuqiang Wang, Yifan Han, K W Michael Siu, Simon Ming Yuen Lee, Ivan K Chu
JournalFree radical biology & medicine (Free Radic Biol Med) Vol. 84 Pg. 331-343 (Jul 2015) ISSN: 1873-4596 [Electronic] United States
PMID25769424 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 Elsevier Inc. All rights reserved.
Chemical References
  • Antiparkinson Agents
  • Flavonoids
  • Hydroxybenzoates
  • NF-E2-Related Factor 2
  • Neuroprotective Agents
  • Nfe2l2 protein, rat
  • Proteome
  • Rela protein, rat
  • Transcription Factor RelA
  • Nitric Oxide
  • protocatechuic acid
  • chrysin
  • Nitric Oxide Synthase Type II
  • Nos2 protein, rat
  • Heme Oxygenase-1
Topics
  • Animals
  • Antiparkinson Agents (pharmacology, therapeutic use)
  • Dopaminergic Neurons (drug effects, physiology)
  • Drug Evaluation, Preclinical
  • Flavonoids (pharmacology, therapeutic use)
  • Heme Oxygenase-1 (metabolism)
  • Hydroxybenzoates (pharmacology, therapeutic use)
  • NF-E2-Related Factor 2 (metabolism)
  • Neuroprotective Agents (pharmacology, therapeutic use)
  • Nitric Oxide (metabolism)
  • Nitric Oxide Synthase Type II (metabolism)
  • Oxidative Stress
  • PC12 Cells
  • Parkinson Disease (drug therapy)
  • Proteome (metabolism)
  • Proteomics
  • Rats
  • Transcription Factor RelA (metabolism)
  • Zebrafish

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: